inclusion criteria: * documented informed consent of the participant * age \>=18 years * eastern cooperative oncology group (ecog) =\<1 * allogeneic or autologous hematopoietic cell transplant (hct), cellular therapy (chimeric antigen receptor \[car\] t-cell) recipients who are at \>= 3 months of infusion date of respective regimen * platelets \>= 50,000/mm\^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * white blood cells (wbcs) \>= 1000/mm\^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * total bilirubin \< 1.5 x upper limit of normal (uln) (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * aspartate aminotransferase (ast) \< 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * alanine aminotransferase (alt) \< 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * creatinine \< 1.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * negative covid-19 pcr test * women of childbearing potential (wocbp): negative urine or serum pregnancy test (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated). if the urine pregnancy test is inconclusive a serum pregnancy test will be required * agreement by females and males of childbearing potential\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy * childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)

inclusion criteria: * documented informed consent of the participant * age \>=18 years * eastern cooperative oncology group (ecog) =\<1 * allogeneic or autologous hematopoietic cell transplant (hct), cellular therapy (chimeric antigen receptor \[car\] t-cell) recipients who are at \>= 3 months of infusion date of respective regimen * platelets \>= 50,000/mm\^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * white blood cells (wbcs) \>= 1000/mm\^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * total bilirubin \< 1.5 x upper limit of normal (uln) (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * aspartate aminotransferase (ast) \< 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * alanine aminotransferase (alt) \< 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * creatinine \< 1.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) * negative covid-19 pcr test * women of childbearing potential (wocbp): negative urine or serum pregnancy test (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated). if the urine pregnancy test is inconclusive a serum pregnancy test will be required * agreement by females and males of childbearing potential\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy * childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)

inclusion criteria: documented informed consent of the participant age >=18 years eastern cooperative oncology group (ecog) =<1 allogeneic or autologous hematopoietic cell transplant (hct), cellular therapy (chimeric antigen receptor [car] t-cell) recipients who are at >= 3 months of infusion date of respective regimen platelets >= 50,000/mm^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) white blood cells (wbcs) >= 1000/mm^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) total bilirubin < 1.5 x upper limit of normal (uln) (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) aspartate aminotransferase (ast) < 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) alanine aminotransferase (alt) < 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) creatinine < 1.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) negative covid-19 pcr test women of childbearing potential (wocbp): negative urine or serum pregnancy test (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated). if the urine pregnancy test is inconclusive a serum pregnancy test will be required agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

inclusion criteria: documented informed consent of the participant age >=18 years eastern cooperative oncology group (ecog) =<1 allogeneic or autologous hematopoietic cell transplant (hct), cellular therapy (chimeric antigen receptor [car] t-cell) recipients who are at >= 3 months of infusion date of respective regimen platelets >= 50,000/mm^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) white blood cells (wbcs) >= 1000/mm^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) total bilirubin < 1.5 x upper limit of normal (uln) (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) aspartate aminotransferase (ast) < 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) alanine aminotransferase (alt) < 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) creatinine < 1.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) negative covid-19 pcr test women of childbearing potential (wocbp): negative urine or serum pregnancy test (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated). if the urine pregnancy test is inconclusive a serum pregnancy test will be required agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

inclusion criteria: - documented informed consent of the participant - age >=18 years - eastern cooperative oncology group (ecog) =< 2 - allogeneic or autologous hematopoietic cell transplant (hct), cellular therapy (chimeric antigen receptor [car] t-cell) recipients who are at >= 3 months of infusion date of respective regimen - platelets >= 50,000/mm^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - white blood cells (wbcs) >= 1000/mm^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - total bilirubin < 1.5 x upper limit of normal (uln) (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - aspartate aminotransferase (ast) < 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - alanine aminotransferase (alt) < 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - creatinine < 1.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - women of childbearing potential (wocbp): negative urine or serum pregnancy test (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated). if the urine pregnancy test is inconclusive a serum pregnancy test will be required - agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy - childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

inclusion criteria: - documented informed consent of the participant - age >=18 years - eastern cooperative oncology group (ecog) =< 2 - allogeneic or autologous hematopoietic cell transplant (hct), cellular therapy (chimeric antigen receptor [car] t-cell) recipients who are at >= 3 months of infusion date of respective regimen - platelets >= 50,000/mm^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - white blood cells (wbcs) >= 1000/mm^3 (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - total bilirubin < 1.5 x upper limit of normal (uln) (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - aspartate aminotransferase (ast) < 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - alanine aminotransferase (alt) < 2.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - creatinine < 1.5 x uln (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated) - women of childbearing potential (wocbp): negative urine or serum pregnancy test (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated). if the urine pregnancy test is inconclusive a serum pregnancy test will be required - agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy - childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)